INHALED BUDESONIDE THERAPY FOR PATIENTS WITH STABLE COPD

被引:44
作者
WEINER, P [1 ]
WEINER, M [1 ]
AZGAD, Y [1 ]
ZAMIR, D [1 ]
机构
[1] INST RESP DIS, HADERA, ISRAEL
关键词
INHALED BUDESONIDE; STABLE COPD PATIENTS;
D O I
10.1378/chest.108.6.1568
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
A significant minority of patients with COPD have favorable response to corticosteroid treatment. In addition, the benefit of corticosteroid treatment may be outweighed by the side effects. Long-term administration of inhaled steroids is a safe means of treatment. We hypothesized that treatment with high-dose inhaled budesonide would improve clinical symptoms and pulmonary function in subjects with COPD, and that the response to inhaled beta(2)-agonist will serve to individualize steroid responders. We compared a 6-week course of 800 mu g/d inhaled budesonide with placebo, separated by 4 weeks when no medication was taken, in a double-blind crossover trial, in 8 patients responding to inhaled beta(2)-agonist, and in 22 nonresponders with stable COPD. In six of eight ''responders to beta(2)-agonist,'' there was a significant improvement in the FEV(1) (defined as greater than or equal to 20%) following inhaled budesonide, as compared with placebo. In the 22 ''nonresponders to beta(2)-agonist,'' there was no significant improvement in the mean FEV(1) (1.41+/-0.1 L before, and 1.61+/-0.1 L after treatment) with inhaled budesonide or placebo. Over the 6-week course of treatment by either budesonide or placebo, the nonresponders reported similar beta(2)-agonist consumption (4.8+/-0.2 and 5.0+/-0.1 puffs per patient per day, respectively). However, there was a significant difference between the two periods of treatment in the responders as for the mean daily number of beta(2)-agonist inhalations (2.4+/-0.1 in the budesonide period as compared with 5.3+/-0.1 in the placebo period; p<0.005). We conclude that treatment with inhaled steroids improved spirometry data and inhaled beta(2)-agonist consumption in about 25% of patients with stable COPD, and this rate is increased to about 75% in patients who respond to beta(2)-agonist inhalation.
引用
收藏
页码:1568 / 1571
页数:4
相关论文
共 25 条
[1]  
ALBERT RK, 1980, ANN INTERN MED, V92, P753, DOI 10.7326/0003-4819-92-6-753
[2]  
BARNES PJ, 1989, NEW ENGL J MED, V321, P1517
[3]  
BEEREL FR, 1971, AM REV RESPIR DIS, V104, P264
[4]  
BICKERMAN H, 1963, NEW ENGL J MED, V268, P226
[5]   TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE WITH CORTICOSTEROIDS - COMPARISON OF DAILY VS ALTERNATE-DAY THERAPY [J].
BLAIR, GP ;
LIGHT, RW .
CHEST, 1984, 86 (04) :524-528
[6]   ORAL CORTICOSTEROID-THERAPY FOR PATIENTS WITH STABLE CHRONIC OBSTRUCTIVE PULMONARY-DISEASE - A METAANALYSIS [J].
CALLAHAN, CM ;
DITTUS, RS ;
KATZ, BP .
ANNALS OF INTERNAL MEDICINE, 1991, 114 (03) :216-223
[7]   HOW CORTICOSTEROIDS WORK [J].
CLAMAN, HN .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1975, 55 (03) :145-151
[8]  
CLIFTON M, 1962, LANCET, V1, P1311
[9]   CLINICAL COMPLICATIONS OF CORTICOSTEROID THERAPY - SELECTED REVIEW [J].
DUJOVNE, CA ;
AZARNOFF, DL .
MEDICAL CLINICS OF NORTH AMERICA, 1973, 57 (05) :1331-1342
[10]   CORTICOSTEROIDS IN COPD - A CLINICAL-TRIAL AND REASSESSMENT OF THE LITERATURE [J].
ELIASSON, O ;
HOFFMAN, J ;
TRUEB, D ;
FREDERICK, D ;
MCCORMICK, JR .
CHEST, 1986, 89 (04) :484-490